AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$UTHR

MAHON PAUL A sold $4.1M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $497.54 ($495.97–$501.58, $4.13M total) across 7 trades on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHON PAUL A
Published Sep 18, 2026, 8:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 8:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

Provides fresh data on insider sentiment, useful for short‑term trading decisions.

02

Market read

Insider sell may influence short‑term price action but is unlikely to drive long‑term trends.

03

What to watch

Potential upcoming clinical data releases that could offset sell pressure.

Relevance 5/10Novelty 4/10Timing: sale executed on 2026-09-17

Background

Form 4 filing discloses insider transactions required by SEC regulations.

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

Insider Paul Mahon sold 8,300 shares for $4.13M via a 10b5-1 plan, reducing his stake to 45,172 shares.

Expected impact

Potential short-term dip of 1-2% as market digests the insider sell.

Evidence & confidence

A $4M sale by an EVP is material for a mid‑cap biotech, but the size relative to float is limited.

Market effects

Sector

May prompt scrutiny of other insider holdings in the biotech sector.

Regional

Limited to U.S. biotech investors; no broader regional effect.

Global

Minimal global impact beyond UTHR shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company outlook.

Key entities

  • Officer
    Paul Mahon

    EVP & General Counsel of United Therapeutics

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 28
$UTHRMed

United Therapeutics Receives FDA Clearance to Begin Clinical Trial of Inhaled PAH Treatment

United Therapeutics (UTHR) received FDA clearance to start clinical trials for Treprostinil-Iloprost SMI, an inhaled treatment for pulmonary arterial hypertension (PAH). The phase 1 trial will assess safety and tolerability. The therapy aims to address symptom flare-ups between maintenance doses. UTHR plans a phase 2 trial in 2027 if initial results are positive. PAH affects around 500,000 people globally.

finance.yahoo.com2 min
OCT 28
$UTHRMed

FDA clears a trial of a two-drug inhaler that could be the first as-needed therapy for lung artery disease.

The FDA approved a trial for Treprostinil-Iloprost SMI, a potential first as-needed inhaler therapy for pulmonary arterial hypertension (PAH). United Therapeutics plans a phase 1 study in 2026, with a phase 2 study in PAH patients anticipated in 2027. The therapy combines treprostinil and iloprost, aiming to provide episodic symptom relief. United Therapeutics aims to expand its PAH treatment portfolio.

stocktitan.net2 min